Tempest Therapeutics adjourns special meeting due to insufficient votes for governance amendment

Tempest Therapeutics, Inc.

Special meeting on July 27, 2026 adjourned; proposal to replace supermajority voting and allow written consent lacked sufficient votes.
Proposal requires 75% affirmative vote; only 67.7% of shares present, but votes not enough to approve.
Meeting reconvenes August 17, 2026; previously submitted proxies remain valid unless revoked.
Company engaged Sodali & Co. to assist with obtaining adequate votes for the proposal.
Record date remains May 28, 2026; no changes to the proposal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.